Revisiting Miotolan (Furazabol): The Obscure and Brief Oral Steroid

Examining Its Purported Effects and Limited Bodybuilding History

Background and Development

Miotolan contains the obscure steroid compound furazabol, which is a derivative of DHT. Furazabol was first synthesized by scientists in the 1960s as part of early research into modifying testosterone and DHT hormones.

It possesses a 17-alpha-methyl group like Winstrol to enable oral administration and resist liver metabolism when ingested. However, unlike Winstrol, furazabol does not negatively affect cholesterol and may even improve HDL and LDL lipid profiles according to some data.

Furazabol never gained much popularity or widespread use compared to other oral steroids. It was produced only briefly before disappearing from pharmaceutical development. Supply remained extremely limited even on black markets.

Discovery by Bodybuilders

In the 1970s and 80s, bodybuilders experimented briefly with furazabol in the form of Miotolan tablets. Doses ranged from 50-100 mg daily taken orally for cycles of 4-6 weeks typically.

It was hoped that Miotolan could provide comparable gains to Winstrol with the added benefit of the cholesterol effects. However, results proved underwhelming compared to rapidly emerging DHT-based steroids.

While the cholesterol properties were interesting on paper, real-world results could not match the performance of newer steroids. Within just a few years, Miotolan had faded into obscurity as better options surfaced.

Today Miotolan remains extremely rare, with virtually no demand and no pharmaceutical supplies. While an intriguing novelty item, furazabol ultimately proved ineffective and unappealing for most bodybuilding purposes.

In summary, Miotolan/Furazabol represented a failed oral steroid experiment that did not gain traction among athletes even during its brief lifespan in the 20th century.